Trade Summary

2 days ago, BRYNJELSEN SEAN, serving as President & CEO at Eton Pharmaceuticals, Inc. (ETON), sold 120,000 shares at $31.88 per share, for a total transaction value of $3,825,716.92. Following this transaction, BRYNJELSEN SEAN now holds 833,694 shares of ETON.

This sale represents a 12.58% decrease in BRYNJELSEN SEAN's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Thursday, May 28, 2026 and publicly disclosed via SEC Form 4 filing on Friday, May 29, 2026 at 4:16 PM ET, 1 day after the trade was made.

Eton Pharmaceuticals, Inc. operates in the HEALTHCARE sector, specifically within the DRUG MANUFACTURERS - SPECIALTY & GENERIC industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.